January 27, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that CARTITUDE-4, the Phase 3 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma, met its primary endpoint of showing a statistically significant improvement in progression-free survival (PFS) compared to standard therapy at the study’s first pre-specified interim analysis. The study has been unblinded following the recommendation of an independent data monitoring committee.
CARTITUDO-4 (NCT04181827) studium primum internationale, randomized, apertum-label Phase 3 studium aestimandi efficaciam et salutem a CAR-T illic versus pomalidomide, bortezomib et dexamethasone (PVd) vel daratumumab, pomalidomide et dexamethasone (DPd) in aegris adultis cum relapso et lenalidomido-refractorio myeloma multiplici, qui unam ad tres priores lineas therapiae recepit.
Primus finis studii est PFS. Secundae fines includunt salutem, altiore salutem (OS), minimam morbum residua (MRD) negativum et altiore rate responsionis (ORR). Aegroti sequentur fines primarios et secundarios sicut pars studii CARTITUDI-IV.
“Autologous CAR-T cell therapy represents a major breakthrough in cancer treatment, and topline results from CARTITUDE-4 support our continuous efforts to bring this treatment option to patients with multa myeloma in various stages of disease progression,” Lida Pacaud, M.D., Vice President of Clinical Development and Medical Affairs at Legend Biotech, said.
Proventus e studio CARTITUDO-4 occurrenti medicinae occurrenti exhibebitur et disputationes cum auctoritate sanitatis de subiectis regulatoriis potentialibus adiuvabit.
CARVYKTI® Indicationes et TRACTATIO
CARVYKTI® (Ciltacabtagen autoleucel) est B-cell maturatio antigenæ (BCMA) directa genetice modificata autologa T cell immunotherapy curationem aegrorum adultorum cum myeloma multiplici relapso vel refractorio indicari, post quattuor vel plures priores lineas therapiae, inhibitor proteasome, agentis immunomodulatoris, et anti-CD38 monoclonalis anticorpus.
WARNINGS pertinent,
CYTOKINE RELEASE SYNDROME (CRS) inter mortiferum vel vita- minaces, occurrit sequenti cura cum CARVYKTI® in 95% (92/97) aegrorum ciltacabtagen autoleucel recipiendi. Gradus 3 vel superior CRS (2019 ASTCT gradus) in 5% (5/97) aegrorum acciderunt, cum Grade 5 CRS in 1 patiente relatum est. Tempus medianum ad incursus CRS erat 7 dierum (range: 1-12 dies). Frequentissima manifestationes CRS inclusa pyrexia (100%), hypotension (43%), aspartata aminotransferase (AST) (22%), frigora (15%) aucta, alaninum aminotransferasum (ALT) (14%) auctum et sinum tachycardium (ALT) (11%) et sinum tachycardium (. 3%). Gradus XNUMX vel eventus superiores cum CRS inclusa aucta AST et ALT, hyperbilirubinemia, hypotension, pyrexia, hypoxia, defectus respiratorii, iniuria renis acuta, coagulatio intravascularis disseminata, HLH/MAS, angina pectoris, supraventricularis et ventriculi tachycardia, defectus, myalgias, auctus. C‑reactivum interdum, ferritinum, sanguinem alcalina phosphatase et gamma-glutamyl transferase.
Cognoscere CRS ex propositione clinica. Alias febres, hypoxias et hypotensiones causas aestimare et tractare. CRS relatum est cum inventis HLH/MAS sociandis, et physiologia syndromorum aliud incidere potest. HLH/MAS potentia vitae conditio est minax. In patientibus progressivis indicia CRS vel refractoria CRS non obstante curatione aestimanda pro testimonio HLH/MAS.
Sexaginta undequadraginta 97 (71%) aegros tocilizumab et/vel corticosteroidem pro CRS receperunt post infusionem ciltacabtageni autoleucelis. Quadraginta quattuor (45%) aegros tantum tocilizumab receperunt, ex quibus 33 (34%) unum dosem et 11 (11%) plus quam unum dosi acceperunt; Aegri 24. (25%) tocilizumab et corticosteroides acceperunt, et unum aegrotum (1%) corticosteroides tantum receperunt. Curare ut minimum duarum dosarum tocilizumab praesto sint ante infusionem CARVYKTI.®.
Monitor aegros saltem cotidie pro X diebus sequentibus CARVYKTI® infusio ad facilitatem sanitatis REMS-certificatae per signa et indicia CRS. Aegri monitoris signa vel indicia CRS pro saltem 4 septimanis post infusionem. Ad primum signum CRS, statim curationem adminicula cura, tocilizumab, vel tocilizumab et corticosteroides instituunt.
Con- silium aegrorum ad curationem immediatam medicinae quaerendam debent signa vel indicia CRS quovis tempore occurrere.
NEUROLOGIC TOXICITIES, quae severa, minax vel funesta sit, sequenti cura occurrit cum CARVYKTI .®. Toxicitates neurologicae includuntur ICANS, neurologica toxicitas cum signis et symptomata parkinsonismi, Guillain-Barré Syndroma, neuropathia peripherica, et paralyticus nervus cranialis. Consule aegros de signis et symptomatibus harum toxicitatum neurologicarum, et de tardae naturae impetu quarundam harum toxicitatum. Aegros instrue ut medicinae operam immediatam ad ulteriora aestimationem et administrationem quaerant, si signa vel symptomata quarumlibet harum toxicitatum neurologicarum quovis tempore occurrant.
Altiore, unum vel plura subtypa toxicitatis neurologicae de quibus infra acciderunt sequentia ciltacabtagena autoleucella in 26% (25/97) aegrorum, e quibus 11% (11/97) aegrorum gradus 3 vel eventus superiores experti sunt. Haec subtypa neurologicorum toxicitatum in duobus studiis permanentibus observabantur.
Immunis effector Cell-Associated Syndrome Neurotoxicity (ICANS): Aegris sentiant pestiferum vel minacem vitalem ICANS sequentem curationem cum CARVYKTI®incluso ante CRS concursu, simul cum CRS, post CRS resolutionem, vel in absentia CRS. ICANS factum est in 23% (22/97) de aegris acceptis ciltacabtagenis autoleucellis excepto Grade 3 vel 4 eventuum in 3% (3/97) et Gradus 5 (fatales) eventus in 2% (2/97). Tempus medianum ad oppugnationem ICANS erat 8 dierum (1-28 dierum). 22 omnes cum ICANS aegros habuit CRS. Frequentissima (≥5%) manifestatio ICANS includitur encephalopathy (23%), aphasia (8%) et capitis (6%).
Monitor aegros saltem cotidie pro X diebus sequentibus CARVYKTI® infusio apud facilitas sanitatis REMS‑ nuntiatae signa et indicia ICANS. Alias causas excludit ICANS symptomata. Aegri monitoris signa vel indicia ICANS per quattuor saltem septimanas post infusionem prompte tractant. Neurologic toxicitas cura adminicula et/vel corticosteroides prout opus est tractari debet.
Parkinsonismus: De 25 aegris in CARTITUDO-1 studio experiendi omnem neurotoxicitatem, quinque aegros masculi toxicitatem neurologicam habuerunt cum pluribus signis et symptomatibus parkinsonismi, distinctis ab effectore immune syndrome neurotoxicitatis-consociatae (ICANS). Toxicitas neurologica cum parkinsonismo relata est in aliis iudiciis permanentibus de ciltacabtageni autoleucelis. Aegroti symptomata parkinsoniana et non parkinsoniana, quae tremorem, bradykinesiam, motus involuntarium, stereotypum, amissionem motus spontanei, facies palliata, acedia, plana affectio, lassitudo, rigiditas, retardatio psychomotoria, micrographia, dysgraphia, apraxia, lethargia, confusio, somnus. , amissio conscientiae, morae reflexes, hyperreflexia, damnum memoriae, difficultas deglutitio, alvus incontinentia, casus, status inclinatus, commiscens incessus, debilitas musculi et tabes, distemperantia motoria, amissio motoria et sensoria, mutismus akineticus, et lobus frontalis emissio signa. Incursus medius parkinsonismi in 5 aegris in CARTITUDE-1 fuit 43 dies (per 15-108) ab infusione ciltacabtageni autoleucelis.
Aegri monitores sunt signa et indicia parkinsonismi quae in concursu differri possunt et cum cura adminicula remediis administrari possunt. Informatio efficacia limitata est cum medicamentis adhibitis ad curationem morbi Parkinson, ad emendationem vel solutionem symptomatis parkinsonismi sequentis CARVYKTI.® curatio.
Guillain-Barré Syndrome: Exitus funestus sequens Guillain-Barré Syndrome (GBS) in alio studio permanente ciltacabtageni autoleucelis incidit non obstante curatione cum immunoglobulis intravenosis. Indicia nuntiata includunt consentanea cum Miller-Fisher variantes GBS, encephalopathy, infirmitas motoria, perturbationes loquelae et polyradiculoneuritis.
Monitori GBS. Aegros aestimare neuropathiam periphericam exhibere pro GBS. Considera curationem GBS cum mensuris adminiculis et in coniunctione cum immunoglobulis et plasmatis permutationis, secundum severitatem GBS.
Periphericum Neuropathum: Sex aegris in CARTITUDO-1 periphericis neuropathia evoluta. Hae neuropathiae offeruntur sensoriis, motoriis vel sensorimotis neuropathiis. Medium tempus accessionis symptomatis erat 62 dierum (range 4-136 dierum), duratio mediana neuropathiae peripheriae erat 256 dierum (range 2-465 dierum), inter quae cum neuropathia permanenti. Aegroti, qui neuropathiam periphericam experti sunt, etiam nervorum cranialium paralyticorum experti sunt vel GBS in aliis iudiciis permanentibus ciltacabtageni autoleucelis.
Nervus paralyticus cranialis: Tres aegroti (3.1%) periti nervorum cranialium paralyticorum in CARTITUDE1. Omnes tres aegroti VII nervi cranialis paralytici erant; unus aeger habebat 7th cranialis nervus paralyticus. Medium tempus aggrediendi erat 5 dierum (dies 26-21) sequentes infusionem ciltacabtageni autoleucelis. Eventum 101 et 3 nervi paralytici, 6 nervi cranialis bilateralis, nervorum cranialium paralysi post emendationem crescente, et neuropathiae periphericae eventum in patientibus nervi paralytici in permanentibus iudiciis ciltacabtageni autoleucelis etiam relati sunt. Aegri monitoris sunt signa et indicia nervorum cranialium paralyticorum. Considera administrationem cum corticosteroideis systemicis, secundum gravitatem et progressionem signorum et symptomatum.
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)/MACROPHAGE ACTIVATION SYNDROME (MAS): funesta HLH in uno passo acciderunt (1%), post 99 dies ciltacabtagen autoleucel. The HLH event was preceded by CRS diuturna 97 dierum. Manifestationes HLH/MAS includunt hypotension, hypoxia cum damno diffuso alveolaris, coagulopathy, cytopenia, et multi-organi distemperantia, inclusa dysfunctione renum. HLH condicio vitae imminens est cum magna mortalitatis rate, nisi mature cognoscitur et tractatur. Curatio HLH/MAS administranda est per signa institutionalia.
CARVYKTI® REMS': Propter periculum CRS et toxicitates neurologicae, CARVYKTI® praesto est nisi per rationem restrictam sub Risk Aestimatio et Mitigatio Strategy (REMS) dicta CARVYKTI® REMS.
PRONUNTIATUS et recurrentes CYTOPENIAS: Patients may exhibit prolonged and recurrent cytopenias following lymphodepleting chemotherapy and CARVYKTI® infusion. One patient underwent autologous stem cell therapy for hematopoietic reconstitution due to prolonged thrombocytopenia.
In CARTITUDO-1, 30% (29/97) aegrorum periti longi Gradus 3 vel 4 neutropenia et 41% (40/97) aegrorum periti longi Gradus 3 vel 4 thrombocytopenia quae ante diem 30 sequentis ciltacabtageni autoleucelis infusione non resolvuntur.
Gradus recurrentes 3 vel 4 neutropenia, thrombocytopenia, lymphopenia et anemia visa sunt in 63% (61/97), 18% (17/97), 60% (58/97), et 37% (36/97) post recuperationem e initialis Gradus 3 vel 4 cytopenia sequenti infusione. Post diem 60 sequentes ciltacabtageni autoleucelis infusio, 31%, 12% et 6% aegrorum recursu Gradus 3 vel lymphopenia superior, neutropenia et thrombocytopenia, respective, post primam receptam Gradus 3 vel 4 cytopenia. Octoginta septem centesimas (84/97) aegrorum habuit unum, duos vel tres vel plures recursus Gradus 3 vel 4 cytopenias post recuperationem initialem Gradus 3 vel 4 cytopenia. Sex et 11 aegroti Gradus 3 vel 4 neutropenia et thrombocytopenia respective tempore mortis habuerunt.
Monitor sanguinis numerat prior et post CARVYKTI® infusio. Cytopenias curo cum factores incrementi et transfusio sanguinis producti subsidii secundum normas institutionales locales.
infectiones: CARVYKTI® aegris cum activo infectio vel inflammatoriae perturbationes dari non debet. Gravis, vita-minaces vel pestifera contagione in aegris facta sunt post CARVYKTI® infusione.
Infectiones (omnes gradus) anno 57 (59%) facta sunt. Gradus 3 vel 4 infectiones factae sunt in 23% (22/97) aegrorum; Gradus 3 vel 4 contagio cum pathogeni non specificata facta sunt in 17%, infectiones virales in 7%, infectiones bacteriales in 1%, et infectiones fungalales in 1% aegrorum. Super quattuor aegros Gradus 5 infectiones habebant: abscessus pulmonis (n=1), sepsis (n=2) et pneumonia (n=1).
Monitor aegros ad signa et indicia contagionis ante et post CARVYKTI® infusion and treat patients appropriately. Administer prophylactic, pre-emptive and/or therapeutic antimicrobials according to the standard institutional guidelines. Febrile neutropenia was observed in 10% of patients after ciltacabtagene autoleucel infusion, and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids and other supportive care, as medically indicated.
Reactivatio Viralis: Hepatitis B virus (HBV) reactivatio, in quibusdam casibus resultantibus in hepatitis, hepatis, defectione et morte hepatis, fieri potest in aegris cum hypogammaglobulinemia. Praestare protegendo pro Cytomegalovirus (CMV), HBV, hepatitis C virus (HCV), et virus immuno- rum humanorum (HIV), vel quaevis agentia infectiosa, si secundum normas clinicas ante collectionem cellularum fabricandis amet indicatis. Considera therapiam antiviralem ad reactivationem viralem per normas institutionales locales / praxim clinicam.
HYPOGAMMAGLOBULINEMIA relatum est ut eventus adversae in 12% (12/97) aegrorum; laboratorium Igg gradus infra 500 mg/dL incidit post infusionem 92% (89/97) aegrorum. Monitor gradus immunoglobulinorum post curationem CARVYKTI® et administra IVIG pro IGG <400 mg/dL. Curo per normas institutionales locales, inter infectio cautiones et prophylaxem antibioticam vel antiviralem.
Usus vitae Vaccines: Tutas immunizationis cum vaccina virali viva durante vel sequenti CARVYKTI® curatio non studuit. Vaccinatio cum vaccino virus vivo non commendatur per VI saltem septimanas ante initium chymographiae lymphodepletionis, durante CARVYKTI.® curatio, et donec immunis recuperatio sequitur curationem CARVYKTI®.
HYPERSENSITIVITY reactiones Infusio aegrorum sequentium ciltacabtageni autoleucel infusio 5% (5/97) facta sunt. Gravis reactiones hypersensivitatis, cum anaphylaxi, fieri potest propter dimethyl sulfoxidi (DMSO) in CARVYKTI®. Aegroti diligenter viverra debent post infusionem signa et indicia gravis reactionis pro II horis. Prompte tracta et apte secundum hypersensilitatis reactionem severitatem administrare.
DE SECUNDA Malignantia: Aegroti secundas malignitates explicari possunt. Monitor vitam desiderare secundas malignitates. In eventu quod secundaria malignitas incidit, contactum Janssen Biotech, Inc., at 1-800-526-7736 nuntiare et obtinere instructiones de collectione patientis exemplaria ad probandum secundae malignitatis cellae originem.
DE EFFECTIBUS BONUM USUS PERITUS hostes propelli ac submoveri velit: Ob potentialitatem eventuum neurologicorum, incluso status mentis mutatus, invasiones, declinationes neurocognitivae, vel neuropathiae, aegroti periclitantur ob conscientiam vel coordinationem alteratae vel diminutae in 8 septimanis post CARVYKTI.® infusio. Aegris mone ut abstineant a pulsis et susceptis occupationibus vel activitate ancipitibus, ut gravia vel potentialiter periculosa machinatione operandi durante hoc initiali tempore, et in eventu novorum incursionum quarumlibet toxicitatum neurologicarum.
adversa reactiones
Frequentissima non-laboratoriae motus adversae (incidentia maior quam 20%) sunt pyrexia, cytokina syndrome emissio, hypogammaglobulinemia, hypotension, dolor musculoskeletalis, lassitudo, infectiones pathogenis non specificati, tussis, frigora, diarrhoea, nausea, encephalopathy, appetitus decrescentes, superiores. tractus respiratorii contagio, capitis, tachycardia, vertigo, dyspnoea, hydropicus, infectiones virales, coagulopathy, constipatio, vomitus. Frequentissima laboratorium reactiones adversae (incidentiam maiorem quam vel aequalem ad 50%) includunt thrombocytopenia, neutropenia, anemia, elevatio aminotransferase, et hypoalbuminemia.
CAR T-Lorem est inter breakthrough curationem ad quaedam genera carcinomata sanguinis. Sunt plus quam DCCL ongoing orci iudiciis in CAR T-Lorem In Sina ad praesens. Aegris qui volunt scribere possunt contact CancerFax patientes estote helpline in whatsapp + 91 96 1588 1588 an email ut info@cancerfax.com.
Quaeso legere plena prescription inter Boxed Admonitio ad CARVYKTI®.
DE CARVYKTI® (CILTACABTAGENE AUTOLEUCEL; CILTA-CEL)
Ciltacabtagene autoleucel is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express TNF. BCMA is primarily expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B-cells and plasma cells. The cilta-cel CAR protein features two BCMA-targeting single domain antibodies designed to confer high avidity against human BCMA. Upon binding to BCMA-expressing cells, the CAR promotes T-cell activation, expansion, and elimination of target cells.[1]
Mense Decembri 2017, Legenda Biotech in exclusivam licentiam et cooperationem terrarum iniit cum Janssen Biotech, Inc.
In February 2022, cilta-cel was approved by the U.S. Food and Drug Administration (FDA) under the brand name CARVYKTI® for the treatment of adults with relapsed or refractory multiple myeloma. In May 2022, the European Commission (EC) granted conditional marketing authorization of CARVYKTI® for the treatment of adults with relapsed and refractory multiple myeloma.[3] In September 2022, Japan’s Ministry of Health, Labour and Welfare (MHLW) approved CARVYKTI®.[4] Cilta-cel was granted Breakthrough Therapy Designation in the U.S. in December 2019 and in China in August 2020. In addition, cilta-cel received a PRIority MEdicines (PRIME) designation from the European Commission in April 2019. Cilta-cel also received Orphan Drug Designation from the U.S. FDA in February 2019, from the European Commission in February 2020, and from the Pharmaceuticals and Medicinal Devices Agency (PMDA) in Japan in June 2020. In March 2022, the European Medicines Agency’s Committee for Orphan Medicinal Products recommended by consensus that the orphan designation for cilta-cel be maintained on the basis of clinical data demonstrating improved and sustained complete response rates following treatment.
DE MULTIPLICA MYELOMA
Multa myeloma insanabilis sanguinem cancer that starts in the bone marrow and is characterized by an excessive proliferation of plasma cells. In 2023, it is estimated that more than 35,000 people will be diagnosed with multiple myeloma, and more than 12,000 people will die from the disease in the U.S. While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed due to symptoms that can include bone problems, low blood counts, calcium elevation, kidney problems or infections.[8] Although treatment may result in remission, unfortunately, patients will most likely relapse. Patients who relapse after treatment with standard therapies, including protease inhibitors, immunomodulatory agents, and an anti-CD38 monoclonal antibody, have poor prognoses and few treatment options available.
[1] CARVYKTI™ Praescribens Informationem. Horsham, PA: Janssen Biotech, Inc.
[2] CARVYKTI (ciltacabtagena autoleucella), BCMA directa CAR-T Therapy, US FDA Approbatio suscipit curationem aegroti adulti cum Relapso vel Refractione Multiplex Myeloma. Available at: https://legendbiotech.com/legend-news/carvykti-ciltacabtagen-autoleucel-bcma-directed-car-t-therapy-receives-us-fda-approval-for-the-treatment-of-adult-patientes -cum-relapsum vel refracta-multa myeloma/. Accessit Octobris MMXXII.
[3] CARVYKTI (ciltacabtagne autoleucel) Approbatio conditionalis concessa a Commissione Europaea de curatione aegrorum cum relapso et refractorio Multiplici Myeloma. Available at: https://legendbiotech.com/legend-news/carvykti-ciltacabtagene-autoleucel-granted-conditional-approval-by-the-european-commission-for-the-treatment-of-patients-with-relapsed-and -refractio-multa-myeloma/. Accessit Octobris MMXXII.
[4] CARVYKTI™ (ciltacabtagena autoleucella) Approbationem accipit a Ministerio Sanitatis, Laboris et Salutis (MHLW) ad tractationem aegrorum cum Relapso vel Refractorio Multiplex Myeloma. Available at: https://www.businesswire.com/news/home/20220926005847/en/CARVYKTI%E2%84%A2-ciltacabtagne-autoleucel-Receives-Approval-from-Japan%E2%80%99s-Ministry-of Salutis Laboris et Salutis MHLW pro-curatio patientium cum Relapso seu Refractione Multiplici Myeloma. Accessit Octobris MMXXII.
[5] Commissio Europaea. Community Register of Orphan Medicinal Products. Available at: https://ec.europa.eu/health/documents/community-register/html/o2252.htm. Accessit Octobris MMXXII.
[6] American Societas Oncologiae Fusce. Multiplex myeloma: introductio. https://www.cancer.net/cancer- types/multiple-myeloma/introductio. Accessit Octobris MMXXII.
[7] Societas American Cancri. "Key Statistics de Multiplex Myeloma." Praesto ad: https://www.cancer.org/cancer/multiplex-myeloma/about/key-statistics.html#:~:text=Multa% 20myeloma% 20is% 20a% 20relatively, homines% 20and% 2015% 2C370 20in% 20women). Accessed January MMXXIII.
[8] Cancer Societas Americana. Multiplex myeloma: mane detectio, diagnosis et choragium. https://www.cancer.org/content/dam/CRC/PDF/Public/8740.00.pdf. Accessit Octobris MMXXII.
[9] Rajkumar SV. Multiplex myeloma: 2020 renovatio in diagnosi, periculo-straificatione et administratione. Am J Hematol. 2020;95(5),548-567. doi: 10.1002/ajh.25791.
[10] Kumar SK, Dimopoulos MA, Kastritis E, et al. Naturalis historia myeloma relapsus est, refractoria ad medicamenta immunomodulatoria et inhibitores proteasomes: studium multicenter IMWG. Leukemia. 2017; 31 (11):2443- 2448.
[11] Gandhi UH, Cornell RF, Lakshman A, et al. Eventus aegrorum cum multa myeloma refractorio in CD38- therapia anticorporis monoclonalis iaculis. Leukemia. 2019; 33(9): 2266-2275.
DE TRADITIO BIOTECH
Legenda Biotech est societas globalis biotechnologiae curandae dicata, et unus dies curans, morbos vitales minas. Praetorium in Somersetto, New Jersey, therapias cellulas antecedens elaboramus contra suggestuum technologiarum diversum ordinatam, incluso antigeno receptore chimaerico autologo et allogeneico T-cell, gamma-delta T cellae (gd T) et occisor naturalis (NK) cellulae substructio. immunotherapy. Ex tribus nostris R&D locis circum orbem terrarum has technologias amet applicamus ad inventionem tutae, efficaciae et incisurae therapeuticae pro aegris ubique terrarum.
